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Children aged 0–2 years (i.e., infants) with acute myeloid leukemia (AML) are a peculiar
subgroup of patients in the childhood AML scenario. They present with distinctive
biological and clinical characteristics, including a high prevalence of prognostically unfa-
vorable risk factors and an increased susceptibility to therapy-related toxicity. Remarkable
improvements have been achieved over the last two decades in the treatment of these
patients and their outcome is becoming superimposable to that of the older age groups.
In this review, we will focus on peculiarities of this young subgroup of children with
AML, describing their clinical presentation, the biology of disease, and factors influencing
outcome. Treatment results and toxicity data reported by major collaborative groups are
also summarized and compared.
Keywords: acute myeloid leukemia, infants, prognostic factors, toxicity, hematopoietic stem cell transplantation,
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Introduction
Prognosis of childhood acute myeloid leukemia (AML) has improved significantly over the
past decades, the current probability of cure being approximately 60% in most of the devel-
oped countries (1). This result has been achieved thanks to not only the use of more effective
anti-leukemic agents and significant improvements in supportive care, but also to the progress
made in the stratification of patients with a consequent risk-directed therapy (2, 3). Children
<1 year of age (i.e., infants) with AML represent a peculiar subgroup of patients with distinc-
tive clinical and biological features (1, 2). Infants with AML have been historically deemed
to be high-risk (HR) patients, due to the high prevalence of prognostically unfavorable fea-
tures (4, 5) and a greater vulnerability to treatment-related toxicity (3–5). Nevertheless, dur-
ing the last two decades, many cooperative groups have reported an outcome of infants not
different from that of older children (4, 6–8): in other words, the remarkable differences in
terms of molecular lesions of infant AML (9) seem no longer to be associated with a dismal
prognosis (6–8).
In this review, we provide an overview of the most relevant international studies focused on
infants with AML discussing the clinical features, genetic characteristics, and treatment outcome.
As a preliminary consideration, we emphasize that, over the years, many studies combined data
of children <12months of age with those of 1- to 2-year-old patients in a single group. Although
historically, the conventional definition of infant AML includes children <1-year–old; in this
review, we chose to focus on characteristics of children under 2 years of age, since children under
1 year and those aged between 1 and 2 years have similar features and superimposable survival
results.
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Clinical and Biologic Characteristics of
Infant AML
Clinical Features
Infants with AML present with clinical characteristics distinct
from that of older children, including a higher incidence of acute
monoblastic, myelomonoblastic, and megakaryoblastic leukemia
[M4, M5, and M7 subtypes in the French-American-British
(FAB) classification], higher leukocyte count at diagnosis, as
well as higher frequency of central nervous system (CNS) and
extramedullary involvement (2, 4). Indeed, nearly 70% of infants
with AML have M4/M5 and M7 AML (50 and 20% for M4/M5
and M7, respectively) (4, 6–8), while FAB M1 and M2 are most
common subtypes in older children (6, 8).
Young age has also been reported to be associated with the
occurrence of extramedullary organ (usually skin) and CNS
involvement at diagnosis, the latter being defined by the pres-
ence of 5 106/L or more white blood cells (WBCs) in the cere-
brospinal fluid (4, 6, 8). The incidence of CNS disease reported
by major collaborative group spans from 12–24% in children
aged <2 years to 3–7% in older children (4, 6, 8). The higher
incidence of CNS disease may be due to the greater vasculature
of infant leptomeninges (10) and to the prevalence of monoblastic
leukemia in infants, since the leukemia counterpart of monocytes
can retain the physiological ability to migrate into peripheral
tissues and to reach the brain passing through the endothelial cell
cytoplasm (4). Considering other extramedullary organ involve-
ment, data are not univocal, since some studies documented a
higher incidence in children aged <2 years in comparison with
older patients (31–36 vs 21%, P= 0.0015 in one BFM report)
(4), whereas no significant age-related differences have been
reported in other studies [12–15 vs 17–18%, P= 0.8 in the Asso-
ciazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
analysis] (8).
The same kind of discrepancy among different reports pertains
to hyperleukocytosis (i.e., aWBC count greater than 100 109/L)
at diagnosis, since one study reported that infants with AML have
a higher frequency of hyperleukocytosis (28% in patients aged
<1 year vs 14% in children older than 2 years, P= 0.003) (4), while
other groups did not confirm this finding (6–8).
Cytogenetic Abnormalities
The chromosomal aberrations of AML in children younger than
2 years are peculiar and markedly different from those found in
older children (2).
Figure 1A depicts the distribution of the main recurrent cyto-
genetic abnormalities of AML in children younger and older than
2 years of age.
Translocations involving chromosome band 11q23, mostly
in myelomonocytic or monoblastic subtypes, are the most
common recurrent cytogenetic aberrations detected in infants
(9). The global incidence of 11q23/MLL rearrangements ranges
in different studies between 35 and 50% (4–8): the incidence
by partners of 11q23/MLL rearrangements for t(9;11)(p22;q23),
t(10;11)(p12;q23), t(11;19)(q23;p13.1), t(1;11)(q21;q23), and
other translocation gene partners are approximately 10–20, 7–9,
1–4, 4–5, and 15%, respectively (4–8).
Translocation t(1;22)(p13;q13) can be found in a relevant pro-
portion of infants (from 5 to 30%), their AML cytological variant
mainly belonging to the FAB-M7 subtype. A complex karyotype
(defined as three or more cytogenetic alterations, including one
structural, and absence of favorable aberrations, or MLL rear-
rangements) seems to be another cytogenetic feature rather fre-
quent in infants, with reported percentages of occurrence in the
order of 14% under 2 years of age, this value decreasing to 4–7%
in older children (4, 9). Conversely, younger children, particularly
under 1 year of age, show a significantly lower frequency of cyto-
genetically normal (CN)-AML, compared with older children (4,
9).
Another distinctive trait of infant AML is the low frequency of
favorable cytogenetic features, namely core-binding factor (CBF)
abnormalities and t(15;17). In AML-BFM-98 and -2004 studies
(4), no t(8;21) was observed in children under 2 years of age, while
inv (12) or t(16;16) were found in only 4% of patients under 1 year
in contrast with a frequency of 9% in older children (4). Acute
promyelocytic leukemia is also extremely rare in infants, where it
has a frequency of 1–2% compared with percentages of 6–7% in
older children (4, 9).
The t(7;12)(q36;p13) and t(7;12)(q22;p13), often accompanied
by trisomy of chromosome 19 or, in some cases, by trisomy 8,
are also almost exclusive of this age group (13). The incidence of
this latter rearrangement could be underestimated because of the
inherent difficulty in detection through the use of conventional
cytogenetics (14, 15).
Abnormalities of 12p, which characterize a cytogenetic group of
patients with adverse outcome (16), were reported to occur with
higher frequency in infants under 1 year of age (5 vs 1% and 0.3%
in children aged 1–2 years and 2–10 years, respectively) (4).
Molecular Aberrations
The principal molecular aberrations of AML detected in children
younger and older than 2 years of age are detailed in Figure 1B.
Mutations of the nucleophosmin 1 (NPM1) gene, primarily
observed in patients with normal karyotypes and generally asso-
ciated with a favorable prognosis (3, 17), are extremely rare in
infants AML (8, 12, 18). The same consideration applies to the
bi-allelic mutations of CEBPA (19). In the experience of the
Children’s Oncology Group, among 193 infant patients analyzed,
the CEBPA mutation was found in only 2% of cases, in contrast
with 3 and 7% in the 3–10 years and over 10 years age group,
respectively (19).
While, as mentioned above, MLL-gene rearrangements result-
ing from translocations are extremely frequent under the age
of 1 year MLL, partial tandem duplications (PTDs) are rare in
pediatric AML and generally not detected in infants (20).
The prevalence of FLT3-ITDmutation in childhood AML usu-
ally presents stepwise increase with age and thus its frequency
in infant AML is significantly lower (2 and 5% of patients aged
<1 year and 1 to <2 years, respectively) than in older children
(8, 21). The point mutations of the activating loop of the FLT3
receptor (FLT3-TKD) seem to be slightlymore prevalent in infants
than FLT3-ITD, being detected in up to 5% of cases (21).
Regarding RAS-pathway aberrations, patients under and over
2 years of age show almost similar frequencies ofN-RAS (15–20%)
Frontiers in Pediatrics | www.frontiersin.org April 2015 | Volume 3 | Article 372
Masetti et al. Acute myeloid leukemia in infants
FIGURE 1 | Distribution of the main cytogenetic (A) and molecular (B) aberrations reported in children with AML younger and older than 2 years of
age. References: Balgobind et al. (9) and Masetti et al. (11).
and PTPN11 (2–3%) mutations, whereas K-RAS mutations seem
to bemore frequent in children over 2 years (9, 22). Overall, taking
together all RAS-pathway mutations, their frequency in the age
group under and over 2 years is similar (22 vs 21%, respectively)
(9). Likewise, the frequency of activating mutations of the c-KIT
receptor does not differ in infants and older children (5–10% in
both groups) (9).
The recently described cryptic fusion transcript CBFA2T3-
GLIS2, which is a recurrent feature of pediatric FAB-M7 and CN-
AML, predicting poor outcome (11), is much more frequently
detected (9.5%) in infants than in older patients (8).
Prognostic Factors
Several studies have analyzed the clinical and biological factors
influencing the outcome of infant AML, with conflicting results.
A favorable cytogenetics and a blast count after induction therapy
<5% have been shown to be the most powerful risk factor for the
outcome of infant AML (4, 8).
Male gender and hyperleukocytosis were associated with
poorer prognosis in children with AML aged 12months or less
in one study (23). Nevertheless, these data have not been con-
firmed in other studies (4, 7, 24). An analysis of 299 children
with AML treated in four consecutive clinical trials between 1980
and 1997 (24) showed that FAB M4 or M5 was an independent
prognostic factor predicting better outcome in children younger
than 2 years. This finding was confirmed, although at a non-
statistically significant level, in other experiences (7) (3-year event
free survival – EFS of 80.8% reported by the Japanese group vs
56.1%, P= 0.105).
Central nervous system involvement at diagnosis does not
influence the survival of infants with AML, although it is asso-
ciated with a subsequent higher incidence of CNS relapse (2,
8, 24, 25).
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In the majority of studies, the presence ofMLL rearrangements
did not affect outcome (4, 7, 8). One study (24) showed that t(9;11)
confers a favorable outcome (5-years EFS 70 16 vs 25% 7%,
P= 0.01) to children with AML<2 years, but this finding was not
confirmed in other trials (17, 26). Paucity of data do not permit
to speculate on the prognostic role of complex or monosomal
karyotype in infants, while an adverse prognostic effect is evident
for older children (1, 27).
As already mentioned, a recently identified risk factor is
the CBFA2T3-GLIS2 fusion transcript. Indeed, the subgroup of
infants harboring this abnormality have been reported to have a
significantly worse prognosis as compared with CBFA2T3-GLIS2-
negative infants (EFS 32.3 vs 59.6%, P< 0.05) (8).
Treatment of Infant AML
In principle, management of young children with AML does not
differ from that of older children. Neither the use of intensive
chemotherapy nor the eligibility to hematopoietic stem cell trans-
plantation (HSCT) are precluded by the immaturity of organs
(lung, liver, brain) in children younger than 1 year. Differences in
pharmacokinetic and pharmacodynamic profiles of certain drugs
(e.g., cytarabine) could increase the susceptibility of infants to
develop toxicities (see Section “Toxicity”), this observation trans-
lating on one hand into the need of adapting dosages of cytotoxic
drugs and on the other into the opportunity that these peculiar
patients be treated in centers with a recognized expertise. Simi-
larly to what is employed in older children, an induction therapy
combining antracycline and cytarabine (Ara-C) represents the
backbone of initial treatment in use bymany collaborative groups,
while repeated courses of high-dose Ara-C in combination with
other cytotoxic agents are largely used as conventional post-
remission therapy. Allogeneic HSCT has been widely utilized to
consolidate the state of remission also in infants, although the
benefit deriving from this approach in comparison to repeated
courses of chemotherapy has been questioned in recent years in
view of a delicate balance between risk of relapse and late effects.
CNS-directed therapy does not differ from that received by older
children, being based on intrathecal cytarabine injections, with
dose adjusted by age. Cranial radiation has been used (4), but
never under 15months of age due to the high risk of inducing
permanent severe neurological sequels.
The outcome of infants with AML significantly improved over
the last three decades, thanks to the intensification of therapy and
the advances in risk assessment, together with the progress in sup-
portive care (3): the EFS rate has increased from 30% in ‘80s–‘90s
(24, 28) to about 50–60% in recent pediatric AML studies (4, 6,
8). The results of the most important AML trials involving infants
are summarized in Table 1. Head-to-head comparison among all
these results has to be made with caution, in view of different
follow-ups (from 3 to 8 years), different selection of age groups
(<1 year of age or 0–2 years of age), and possible exclusion of
neonates, or of patients experiencing early death (ED).
Treatment Results by Protocols
The most significant experiences (both for numbers of infants
enrolled and observation time) of treatment analyzing separately
the results of infants with AML are summarized below and reflect
different approaches of post-remissional treatment.
Infants treated according theAIEOPAML2002/01 Protocol (8)
received two courses of induction therapy with idarubicin, Ara-C,
and etoposide followed by two consolidation courses (high-dose
Ara-C combinedwith etoposide andmitoxantrone during the first
and second course respectively). The post-remissional treatment
was largely based on autologus or allogeneic HSCT (33). The 8-
year overall survival (OS) and EFS were 74 and 55%, respectively.
The complete remission (CR), ED, induction failure rates, and
cumulative incidence of relapse (82, 3, 14, and 31%, respectively)
did not show any significant differences compared with those of
older children.
A similar approach was reported in the MRC AML-10 and -
12 trials (34) where infants achieving CR, except for good risk
children, were eligible for matched family donor (MFD) HSCT.
The main novelty of the AML-12 trial was a randomization
between four and five courses of chemotherapy. A better out-
come for younger children emerged from the comparison by age,
the 5 years OS and EFS being 65 and 59% vs 56 and 47% in
infants and in children aged 10–15 years, respectively (P= 0.02)
(6). These findings were explained by a lower relapse rate in
infants (P= 0.02) while the CR and ED rates were 89 and 11%
TABLE 1 | Treatment outcome of children younger than 2 years in recent pediatric AML trials.
Study Years of study N° CR (%) IF (%) ED (%) CIR (%) OS (%) EFS (%) References
AIEOP LAM-92 1992–2001 39b – – – – – 51 Pession et al. (29)
AIEOP-AML 2002/01 2002–2011 63a 82 14 3 31 74 55 Masetti et al. (8)
NOPHO-AML93 1993–2001 57b – – – – – 54 Lie et al. (30)
MRC (AML 10, 12) 1994–2002 57a 89 0 11 25 65 59 Webb et al. (6)
ANLL91 1995–1998 35a 91 – – – 76 72 Kawasaki et al. (7)
BFM (AML 98, AML 2004) 1998–2010 125a 85 7.5 7.5 34 61 (AML 98) 44 (AML 98) Creutzig et al. (4)
75 (AML 2004) 51 (AML 2004)
POG 8821 1988–1993 122b 33 22 Ravindranath et al. (31)
LAME 89/91 1988–1998 42a 85 82 (autograft) 37 Perel et al. (32)
15 (Cht)
aStudies including children <1 year of age.
bStudies including children aged 0–2 years.
AIEOP, Associazione Italiana Ematologia e Oncologia Pediatrica; BFM, Berlin-Frankfurt-Munster; LAME, Leucamie Aique Myeloid Enfant; MRC, Medical Research Council; NOPHO,
Nordic Society of Pediatric Hematology and Oncology; POG, Pediatric Oncology Group; Cht, chemotherapy; CIR, cumulative incidence of relapse; CR, complete remission; ED, early
death; EFS, event free survival; IF, induction failure; OS, overall survival; y, years.
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in patients <1 year, similar to those observed in older children
(P= 0.5, P= 0.06). Resistant disease resulted to be less frequent in
younger patients, while the percentage of death during induction
was reported to be higher in infants than in older patients (11 vs
4%, P= 0.06).
The 125 infants enrolled in the AML-BFM-98 (59 patients)
and -2004 (66 patients) trials between 1998 and 2010 (4) (96%
allocated in the HR group, according to their clinical and bio-
logical features and the response to therapy) received a standard
induction therapy, followed by four courses of chemotherapy
including high-doseAra-C and anthracyclines. In theAML-BFM-
2004 trial, patients were randomly assigned to receive liposomal
daunorubicin in place of idarubicin in induction. The 5-year OS
and EFS improved from 61 and 44% in the AML-BFM-98 to 75
and 51% in the -2004 trial, respectively (4). CR rate, OS, EFS, ED,
and resistant disease ofHR infants, and olderHRpatients were not
statistically significant different, being 85, 66, 47, 7.5, and 7.5%,
respectively.
The LAME French Cooperative Group (32) reported outcome
of 42 treated according to studies LAME 89-91 where after an
induction phase of mitoxantrone plus Ara-C, a consolidation
based on high-dose Ara-C and asparaginase was given. As post
consolidation therapy, 14 infants in CR1 underwent AUTO-
HSCT. In all, 17 relapses and two deaths in CR occurred. The EFS
was 37.3%. Disease free-survival (DFS) was 64.7% with autograft
(n= 14) and 15% with chemotherapy alone (n= 18) (P= 0.12),
and OS was, respectively, 82.7 vs 15.7% (P= 0.01). It is of interest
that in this study, despite a satisfactory CR rate in infants (85%),
the high relapse rate resulted in an extremely low OS for those
treated with chemotherapy alone.
The Japanese collaborative group reported a 3-year OS and EFS
of 76 and 72%, respectively, in infants with AML, mainly treated
with intensive chemotherapy only (7). The 35 infants analyzed
received an induction therapy including etoposide, Ara-C, and
mitoxantrone, followed by four different courses of intensification
therapy with etoposide, Ara-C, and anthracyclines, or vincristine.
The outcome results of this study should be compared with
caution to the others, because of the relatively small number of
patients analyzed and the short follow-up.
Role of HSCT for Infant AML
The last decades have seen parallel improvements in
chemotherapy-based and HSCT regimens for the treatment of
infants AML. There is not a general consensus on indication for
HSCT in CR1 for this category, being the use of HSCT mainly
questioned in view of the potentially severe side effects, such as
growth hormone deficiency, abnormal pubertal development,
and hypothyroidism, correlated to the transplant procedure (35–
38). In the absence of randomized studies comparing HSCT with
other types of post-remission therapy in infants, it is extremely
hard to define a clear indication on which infants would benefit
of an allograft. The presence of a matched sibling donor as an
HSCT indication, has, in most protocols, been replaced by risk
assessments based upon disease and response-related factors.
Although the long-term toxicity associated with HSCT cannot
be neglected, in view of the HR characteristics of almost all
infants, transplantation holds the potential to still qualify as the
treatment associated with the lowest risk of leukemia recurrence,
in particular in subgroups of infants with worst prognosis (i.e.,
those with more than 5% blasts at the end of induction therapy
or those carrying unfavorable cytogenetic/molecular lesions). The
AIEOP experience, largely based onHSCT as consolidation shows
how a good outcome, is not compromised by unacceptable TRM
or high late effects rate. In the 2002/01 study (8) where 46 out
of 63 children aged <1 year received HSCT in CR1, the risk of
fatal events occurring after transplantation was extremely low
(i.e., 1%). Since also only 10 out of the 46 infants relapsed, it
is reasonable to speculate that HSCT significantly contributed
to the favorable outcome of patients. This hypothesis is further
corroborated by the observation that an allograft was able to
guarantee continuous CR to 3 out of the 9 patients not responding
to the induction treatment and to 5 out of the 10 patients relapsing
after a first HSCT included in the study (8). As far as the incidence
of side effects is concerned, among transplanted infants in the
AIEOP study, 14% experienced growth deficiency, 3% decreased
cardiac function, 9%hypothyroidism, and 6%developed impaired
cognitive function.
Despite these favorable data, the role of allogeneic HSCT in
CR1 of infants with AML is disputed. Indeed, the Japanese group
reported good outcome in 35 infants, using allogeneic HSCT in
CR1 only in 6 of them (7). Likewise, Creutzig and Colleagues
reported an EFS comparable to that of the AIEOP group using
ALLO HSCT in CR1 in only 14 out of the 125 infants reported
in their more recent study (13 of them were alive and disease
free) (4). They also prospectively evaluated the impact of matched
sibling donor HSCT in children with AML in CR1 showing that
the DFS for children younger than 2 years was not different (46%
vs 53%, P= 0.53) (39). This said it is noteworthy to consider
that children with 11q23 aberrations treated in the AML BFM98
study had a significantly better 5-year DFS when given allogeneic
HSCT in CR1, the advantage offered by transplantation being
evenmore evident when taking into account the 5-yearOS (94 6
vs 52 7% of children treated with chemotherapy only, P= 0.01)
(39). Moreover, in a recent retrospective analysis conducted by
Eurocord/EBMT on 95 infants with AML receiving single-unit
cord blood transplantation after a myeloablative preparation, the
reported 4-year DFS was 82% for those infants who were trans-
planted in CR1 (40).
The issue whether HSCT should be largely employed in infants
with AML in CR1 or rather mainly reserved to relapsing patients
remains unsolved and needs to be addressed in future studies.
Toxicity
Regarding therapy-related toxicity in infant AML, it has been
severely reduced in the last decades due to the advances in the
supportive care. The increased susceptibility to toxicities of infants
patients results from immaturity of lung, liver, and brain function,
as well as a distinctive pharmacokinetics and pharmacodynamics
profile of drugs such as Ara-C (2, 4, 5). These findings have led
to the adjustment of drug dosage on the basis of body weight
(mg/Kg) instead of body surface. High-dose Ara-C was age-
adjusted in children younger than 2 years in some trials because
of reduced clearance of this drug (4, 27, 41).
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The toxicities observed in the Japanese study (7) included 9
septic episodes (4 during induction and 5 during intensification
therapy), 2 cutaneous abscess, 2 viral pneumonia, 1 neurotox-
icity, 1 hemorrhagic cystitis, and 1 hypocalcemia. The major-
ity of the patients developed febrile episodes associated with
myelosuppression.
Regarding gastrointestinal toxicity, Webb et al. did not observe
(6) age-related incidence of oral toxicity (P= 0.8) and nausea
or vomiting (P= 0.01). On the contrary, the study revealed a
higher prevalence of severe diarrhea in younger children, the
incidence decreasing from 38% in infants to 16% in patients aged
10–15 years (P= 0.002).
In the BFM studies (4), infants developed significantly higher
rates of pulmonary problems (34% in infants, 24% in children aged
1–2 years, 14% in older patients, P= 0.01) and compromised gen-
eral condition (50%, 43%, 31% in infants, children aged 1–2 years
and older patients, respectively) after induction. Moreover severe
infections occurred in 42% of infants compared to 29% of chil-
dren aged 2–10 years (P= 0.08). Severe mucositis occurred less
frequently in infants (4, 8). No differences in late effects were
observed between infants who did or did not receive HSCT (59
vs 43%, P= 0.39) (8), but these data need to be confirmed after a
longer follow-up.
Conclusion
In summary, infants with AML represent a cohort of patients
with peculiar clinical and biological features. The presence of
remarkable differences in terms of molecular lesions or clinical
characteristics of infant AML have a limited impact on their
outcome. This latter, after both frontline and relapse treatment,
has improved considerably over the last 10–15 years, being now
super imposable to that of older children in the experiences of
the major collaborative groups. Intensive AML treatment is fea-
sible in this young subgroup, and toxicities are manageable. The
effort of future trials should address defining which subgroups of
infants, considering cytogenetic/molecular features and response
to treatment, require more aggressive therapy including HSCT.
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